Triveni Bio Begins Phase 2 Trial of TRIV-509 in Atopic Dermatitis
Atopic dermatitis (AD) remains the most common chronic inflammatory skin condition, with persistent itch, barrier dysfunction, and inflammation continuing to drive significant disease burden. These ongoing challenges highlight the critical






